Ajinomoto Co., Inc. has completed its procedure to acquire all capital stocks of Althea Technologies, Inc. a US-based biopharmaceutical CDMO for approximately US$ 175 million (approx. JPY 16 billion).
Althea now being a fully consolidated subsidiary of Ajinomoto Co. under the new name Ajinomoto Althea Inc., Ajinomoto Co. plans to expand the business for contract biopharmaceutical development and manufacturing services in the North American market, and to strengthen the Ajinomoto Group’s advanced biomedical business.
Under the new name Ajinomoto Althea, Inc. Rick Hancock will be the president & CEO; co-chaired by Hiroshi Shiragami, Ph.D. (Managing Director) and Magda Marquet, Ph.D. (Founder) will be headquartered in San Diego, California. The company will undertake contract development and manufacturing organisation by providing fill & finish, biologics manufacturing, analytical development, and stability testing services for biopharmaceutical companies.
Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals.